Identification of the SUMO E3 Ligase PIAS1 As a Potential Survival Biomarker in Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 May 12

PMID 28493978

Citations 25

Authors

Ayan Chanda

Angela Chan

Lili Deng

Elizabeth N Kornaga

Emeka K Enwere

Donald G Morris

Shirin Bonni

Affiliations

Soon will be listed here.

Abstract

Metastasis is the ultimate cause of breast cancer related mortality. Epithelial-mesenchymal transition (EMT) is thought to play a crucial role in the metastatic potential of breast cancer. Growing evidence has implicated the SUMO E3 ligase PIAS1 in the regulation of EMT in mammary epithelial cells and breast cancer metastasis. However, the relevance of PIAS1 in human cancer and mechanisms by which PIAS1 might regulate breast cancer metastasis remain to be elucidated. Using tissue-microarray analysis (TMA), we report that the protein abundance and subcellular localization of PIAS1 correlate with disease specific overall survival of a cohort of breast cancer patients. In mechanistic studies, we find that PIAS1 acts via sumoylation of the transcriptional regulator SnoN to suppress invasive growth of MDA-MB-231 human breast cancer cell-derived organoids. Our studies thus identify the SUMO E3 ligase PIAS1 as a prognostic biomarker in breast cancer, and suggest a potential role for the PIAS1-SnoN sumoylation pathway in controlling breast cancer metastasis.

Citing Articles

Application and prospect of organoid technology in breast cancer.

Huang S, Mei Z, Wan A, Zhao M, Qi X Front Immunol. 2024; 15:1413858.

PMID: 39253075 PMC: 11381393. DOI: 10.3389/fimmu.2024.1413858.

PIAS family in cancer: from basic mechanisms to clinical applications.

Li X, Rasul A, Sharif F, Hassan M Front Oncol. 2024; 14:1376633.

PMID: 38590645 PMC: 10999569. DOI: 10.3389/fonc.2024.1376633.

Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis.

Ajithkumar P, Vasantharajan S, Pattison S, McCall J, Rodger E, Chatterjee A Int J Mol Sci. 2024; 25(2).

PMID: 38255946 PMC: 10815915. DOI: 10.3390/ijms25020874.

Human Post-Translational SUMOylation Modification of SARS-CoV-2 Nucleocapsid Protein Enhances Its Interaction Affinity with Itself and Plays a Critical Role in Its Nuclear Translocation.

Madahar V, Dang R, Zhang Q, Liu C, Rodgers V, Liao J Viruses. 2023; 15(7).

PMID: 37515286 PMC: 10384427. DOI: 10.3390/v15071600.

Sumoylated SnoN interacts with HDAC1 and p300/CBP to regulate EMT-associated phenotypes in mammary organoids.

Chanda A, Sarkar A, Deng L, Bonni A, Bonni S Cell Death Dis. 2023; 14(7):405.

PMID: 37414747 PMC: 10326038. DOI: 10.1038/s41419-023-05921-x.

References

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

Weber S, Maass F, Schuemann M, Krause E, Suske G, Bauer U . PRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling. Genes Dev. 2009; 23(1):118-32. PMC: 2632166. DOI: 10.1101/gad.489409. View

Li S, Yang C, Hong Y, Bi H, Zhao F, Liu Y . The transcriptional activity of co-activator AIB1 is regulated by the SUMO E3 ligase PIAS1. Biol Cell. 2012; 104(5):287-96. DOI: 10.1111/boc.201100116. View

Nieto M . The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol. 2011; 27:347-76. DOI: 10.1146/annurev-cellbio-092910-154036. View

Palvimo J . PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription. Biochem Soc Trans. 2007; 35(Pt 6):1405-8. DOI: 10.1042/BST0351405. View

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

Hsu Y, Sarker K, Pot I, Chan A, Netherton S, Bonni S . Sumoylated SnoN represses transcription in a promoter-specific manner. J Biol Chem. 2006; 281(44):33008-18. DOI: 10.1074/jbc.M604380200. View

Malinen M, Toropainen S, Jaaskelainen T, Sahu B, Janne O, Palvimo J . Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells. Mol Cell Endocrinol. 2015; 414:91-8. DOI: 10.1016/j.mce.2015.07.024. View

Kornaga E, Klimowicz A, Guggisberg N, Ogilvie T, Morris D, Webster M . A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort. Mod Pathol. 2016; 29(8):799-809. DOI: 10.1038/modpathol.2016.74. View

10.

Bonni S, Wang H, Causing C, Kavsak P, Stroschein S, Luo K . TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol. 2001; 3(6):587-95. DOI: 10.1038/35078562. View

11.

Gur I, Fujiwara K, Hasegawa K, Yoshikawa K . Necdin promotes ubiquitin-dependent degradation of PIAS1 SUMO E3 ligase. PLoS One. 2014; 9(6):e99503. PMC: 4049815. DOI: 10.1371/journal.pone.0099503. View

12.

Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E . TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. BMC Cancer. 2015; 15:453. PMC: 4453047. DOI: 10.1186/s12885-015-1471-y. View

13.

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View

14.

Gonzalez-Prieto R, Cuijpers S, Kumar R, Hendriks I, Vertegaal A . c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4. Cell Cycle. 2015; 14(12):1859-72. PMC: 4613540. DOI: 10.1080/15384101.2015.1040965. View

15.

Chandhoke A, Karve K, Dadakhujaev S, Netherton S, Deng L, Bonni S . The ubiquitin ligase Smurf2 suppresses TGFβ-induced epithelial-mesenchymal transition in a sumoylation-regulated manner. Cell Death Differ. 2015; 23(5):876-88. PMC: 4832106. DOI: 10.1038/cdd.2015.152. View

16.

Massague J . TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012; 13(10):616-30. PMC: 4027049. DOI: 10.1038/nrm3434. View

17.

Yin X, Xu C, Zheng X, Yuan H, Liu M, Qiu Y . SnoN suppresses TGF-β-induced epithelial-mesenchymal transition and invasion of bladder cancer in a TIF1γ-dependent manner. Oncol Rep. 2016; 36(3):1535-41. DOI: 10.3892/or.2016.4939. View

18.

Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez J . mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst. 2011; 103(20):1552-6. DOI: 10.1093/jnci/djr326. View

19.

Remotti H . Tissue microarrays: construction and use. Methods Mol Biol. 2013; 980:13-28. DOI: 10.1007/978-1-62703-287-2_2. View

20.

Jain S, Singhal S, Francis F, Hajdu C, Wang J, Suriawinata A . Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma. World J Gastroenterol. 2011; 17(35):3994-4000. PMC: 3199557. DOI: 10.3748/wjg.v17.i35.3994. View